晚期糖基化终末产物及其受体对2型糖尿病骨质疏松的影响  

Effects of Advanced Glycation End Products and Their Receptor on Osteoporosis in Type 2 Diabetes Mellitus

作　　者：史佩佩 宫赫[1,2] SHI Peipei;GONG He(Key Laboratory of Biomechanics and Mechanobiology(Beihang University),Ministry of Education,Beijing Advanced Innovation Center for Biomedical Engineering,School of Biological Science and Medical Engineering,Beihang University,Beijing 100191,China;Innovation Center for Medical Engineering&Engineering Medicine,Hangzhou International Innovation Institute,Beihang University,Hangzhou 311115,China)

机构地区：[1]北京航空航天大学生物与医学工程学院,生物力学与力生物学教育部重点实验室,北京市生物医学工程高精尖创新中心,北京100191 [2]杭州市北京航空航天大学国际创新研究院(北京航空航天大学国际创新学院)医工交叉科创中心,杭州311115

出　　处：《医用生物力学》2025年第2期485-491,共7页Journal of Medical Biomechanics

基　　金：国家自然科学基金项目(12272029);杭州市北京航空航天大学国际创新研究院资助项目(2024KQ093)。

摘　　要：2型糖尿病(type 2 diabetes mellitus,T2DM)引发的骨质疏松增加了患者的骨折风险及骨折后死亡率。然而,其具体发病机制尚未明确,目前缺乏有效的预防和治疗手段。本综述首先总结非酶糖基化反应所产生的晚期糖基化终末产物(advanced glycation end products,AGEs)对T2DM骨基质成分、骨结构和力学性能的影响;然后阐述AGEs及其受体(receptor for AGEs,RAGE)导致骨退变的生物学机制;最后探讨有益于骨合成代谢的降糖药物及其他药物通过抑制AGE/RAGE信号通路对骨质量的改善,为T2DM相关骨质疏松的预防和治疗提供潜在的干预靶点和思路。Osteoporosis caused by type 2 diabetes mellitus(T2DM)increases the risk of fracture and postfracture mortality.However,the pathogenesis of the disease remains unclear,resulting in a lack of effective strategies for its prevention and treatment.In this review,firstly,the effects of advanced glycation end products(AGEs)produced by non-enzymatic glycation on bone matrix composition,bone structure,and mechanical properties of T2DM are summarized.Then,the biological mechanism of AGEs and receptor for AGEs(RAGE)affecting bone degeneration in T2DM is clarified.Finally,antidiabetic and other drugs that are beneficial to bone anabolism are discussed.These drugs positively affect bone quality through inhibiting AGE/RAGE signaling pathway.Accordingly,it is expected to provide potential intervention targets and ideas for the prevention and treatment of T2DM-related osteoporosis.

关 键 词：2型糖尿病 骨质疏松 晚期糖基化终末产物 骨转换 药物干预 

分 类 号：R318.01[医药卫生—生物医学工程]